BioTuesdays

Category - News

Depomed
Markets

Leerink starts Depomed at outperform

Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday. “Depomed’s Nucynta for chronic pain provides a differentiated...

March 10, 2016
Executive Moves

Marc Becker joins CRISPR Therapeutics as CFO

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.Mr...

March 10, 2016
TearLab
Developments

TearLab Q4 revenue climbs 28%

Fourth quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) was $6.8-million, up 28% from $5.3-million a year ago. For all of 2015, revenue rose 28% to $25.2-million from $19.7-million for 2014. A net total of 258 TearLab...

March 8, 2016
Executive Moves

Rigel Pharma names Anne-Marie Duliege as CMO

Rigel Pharmaceuticals (NASDAQ:RIGL) has appointed Dr. Anne-Marie Duliege, as CMO, replacing Dr. Elliott Grossbard, who is retiring after 14 years with the company.Dr. Grossbard will remain with the company, advising on...

March 8, 2016
EyeGate Pharmaceuticals
Markets

EyeGate Pharma Acquires Jade Therapeutics

EyeGate Pharmaceuticals (NASDAQ:EYEG) has acquired Jade Therapeutics, a closely-held company developing locally administered, polymer-based products designed to treat poorly-served ophthalmic indications. Jade’s...

March 8, 2016
HCW Logo
Executive Moves

Shaunak Deepak joins H.C. Wainwright

Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also...

March 8, 2016
Nanosphere
Markets

Rodman starts Nanosphere at buy

Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday. “In our view, the company’s Verigene system and test panels are...

March 8, 2016
BioSpecifics Technologies
Markets

Rodman starts BioSpecifics at buy

Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday. The company’s sole product is the...

March 8, 2016